Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged \>2 and \<18 years in two doses (64 mg or 48 mg every 4 weeks) depending on patient's weight. Secondary objectives are to evaluate the pharmacodynamic (PD) profile, the long-term efficacy and safety of olokizumab in patients with polyarticular juvenile idiopathic arthritis aged \>2 and \<18 years.

NCT Number	NCT07517575
Lead Sponsor	R-Pharm International, LLC Collaborators: R-Pharm, Keystat, LLC, Exacte Labs LLC
Conditions	Juvenile Idiopathic Arthritis
Enrollment	71 participants
Start Date	2023-03-17
Primary Completion	2026-09 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-04-08